Haemonetics HAE Balance Sheet Statement
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| $245.44M-20.0% | $306.76M+71.6% | $178.8M-37.1% | $284.47M+9.6% | ||
| $216.86M+7.0% | $202.66M-1.9% | $206.56M+15.3% | $179.14M+12.4% | ||
| $306.37M-16.1% | $365.14M+15.1% | $317.2M+22.3% | $259.38M-11.5% | ||
| $834.88M-10.7% | $934.98M+21.6% | $768.9M-0.1% | $769.72M+1.8% | ||
| $305.76M+7.6% | $284.05M-8.8% | $311.36M+0.2% | $310.89M+20.3% | ||
| $656.37M+8.6% | $604.27M+6.9% | $565.08M+21.2% | $466.23M-0.2% | ||
| $447.66M-1.8% | $455.74M+12.2% | $406.12M+47.3% | $275.77M-11.1% | ||
| —— | $61.6M— | —— | —— | ||
| $2.4B-2.2% | $2.45B+11.6% | $2.2B+13.5% | $1.93B+4.0% | ||
| $51.06M-23.8% | $67M-8.7% | $73.36M+14.7% | $63.93M+9.5% | ||
| —— | —— | —— | —— | ||
| $5.02M-98.3% | $303.56M+2,868% | $10.23M-13.2% | $11.78M-94.5% | ||
| $282.6M-51.1% | $578.11M+92.5% | $300.38M+19.3% | $251.82M-43.1% | ||
| $1.22B+32.4% | $921.23M+15.5% | $797.56M+5.8% | $754.1M+34.8% | ||
| $453K-6.0% | $482K-5.1% | $508K+0.8% | $504K-1.4% | ||
| $279.34M-20.7% | $352.17M-2.3% | $360.46M+42.4% | $253.17M+25.1% | ||
| $796.32M-3.0% | $820.84M-14.5% | $959.96M+17.4% | $818M+9.2% | ||
| $2.4B-2.2% | $2.45B+11.6% | $2.2B+13.5% | $1.93B+4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Haemonetics cover its short-term obligations?
- Its current ratio is 2.95 — current assets exceed current liabilities.
- Where does Haemonetics's balance sheet data come from?
- Every line is extracted from Haemonetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.